Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

Sangeetha Palakurthi, PhD
Published: Thursday, Apr 21, 2016



Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.

SELECTED
LANGUAGE


Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x